Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb CoBMYMP.PFD -10.31%77 EV-to-OCF is 0.05 as of Jul. 26, 2026, which is 100% below its 10-year median of 12.35. GuruFocus rates BMYMP.PFD with a GF Score™ of 77/100. The stock has 7 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks worse than 54.17% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Bristol-Myers Squibb Co's Enterprise Value is $647.00 Mil.
Bristol-Myers Squibb Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $13,306.00 Mil. Therefore, Bristol-Myers Squibb Co's EV-to-OCF for today is 0.05.
The historical rank and industry rank for Bristol-Myers Squibb Co's EV-to-OCF or its related term are showing as below:
BMYMP.PFD'
s EV-to-OCF Range Over the Past 10 Years
Min: 7.43 Med: 12.35 Max: 78.97
Current: 12.23
During the past 13 years, the highest EV-to-OCF of Bristol-Myers Squibb Co was 78.97. The lowest was 7.43. And the median was 12.35.
BMYMP.PFD's EV-to-OCF is ranked worse than 54.17% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.565
vs BMYMP.PFD: 12.23
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bristol-Myers Squibb Co (OTCPK:BMYMP.PFD) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bristol-Myers Squibb Co's PE Ratio (TTM) for today is calculated as:
Bristol-Myers Squibb Co's share price for today is $700.00.
Bristol-Myers Squibb Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMYMP.PFD vs PFE, GILD, AMGN: EV-to-OCF Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's EV-to-OCF falls into.
Bristol-Myers Squibb Co's current Enterprise Value is $647.00 Mil.
Bristol-Myers Squibb Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13,306.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (BMYMP.PFD) has a EV-to-OCF of 0.05 as of Jul. 26, 2026. This is 100% below median its historical median of 12.35. Over the past decade, Bristol-Myers Squibb Co's EV-to-OCF has ranged from 7.43 to 78.97. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #546 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 54.2%.
Is Bristol-Myers Squibb Co's EV-to-OCF too high?
Bristol-Myers Squibb Co's current EV-to-OCF of 0.05 is 100% below median its 10-year median of 12.35. Over the past 10 years, this metric has ranged from a low of 7.43 to a high of 78.97. The Drug Manufacturers industry median EV-to-OCF is 10.57. Bristol-Myers Squibb Co's value of 0.05 is 99.5% below this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #546 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's EV-to-OCF compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #546 out of 1008 companies for EV-to-OCF. This places Bristol-Myers Squibb Co in the lower half of its industry. The industry median EV-to-OCF is 10.57. Bristol-Myers Squibb Co's value of 0.05 is 99.5% below this benchmark. Historically, Bristol-Myers Squibb Co's own EV-to-OCF has ranged from 7.43 to 78.97 over the past decade. While the company's 10-year median is 12.35 vs. the industry median of 10.57, Bristol-Myers Squibb Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.57, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current EV-to-OCF of 0.05 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current EV-to-OCF is 0.05, which is 100% below median its own 10-year median of 12.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (BMYMP.PFD) has a current EV-to-OCF of 0.05. The current EV-to-OCF is 0.05, which is 100% below median its 10-year median of 12.35 and 99.5% below the Drug Manufacturers industry median of 10.57. Bristol-Myers Squibb Co's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BMYMP.PFD), the current EV-to-OCF is 0.05 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
77GF Score
Get the complete analysis for BMYMP.PFD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMYMP.PFD has been successfully added to your 
